ARDD began more than a decade ago as a relatively small meeting in Basel, Switzerland, intended to bring pharmaceutical and academic researchers into closer contact around the emerging science of aging. Its move to Boston reflects the field’s expanding commercial and scientific center of gravity. The 2026 program will cover the full path from fundamental mechanisms of aging to therapeutic discovery, clinical development, regulatory planning, licensing and commercialization. That broad scope is significant because aging is not a single disease with one molecular cause. It is a complex biological process involving genomic instability, altered cellular communication, mitochondrial dysfunction, chronic inflammation, loss of proteostasis, stem-cell exhaustion and changes in tissue regeneration. Turning those mechanisms into medicines requires collaboration among specialists who traditionally worked in separate disciplines.

The meeting’s organizers say the 2026 program will be the broadest in ARDD’s history, with participation from major pharmaceutical companies, biotechnology firms, universities, hospitals, financial institutions, scientific publishers and policy organizations. Alex Zhavoronkov, founder and chief executive officer of Insilico Medicine and a co-chair of ARDD, said the event has evolved into a global platform for dialogue among academia, pharmaceutical companies, startups and investors. He described the concentration of participants as evidence that longevity biotechnology is becoming an increasingly important frontier for drug discovery and healthcare. The significance extends beyond the number of organizations involved: pharmaceutical investment can provide the manufacturing, toxicology, clinical and regulatory infrastructure required to move promising aging interventions from experimental models into human studies.

One of the featured presentations will be delivered by Fiona Marshall, president of Biomedical Research at Novartis, under the title “Reimagining Drug Discovery Through the Lens of Aging Biology.” The program will also include a Pharma Chief Executive Panel featuring Christophe Weber, former chief executive officer of Takeda; Elcin Barker Ergun, chief executive officer of Menarini; Marshall; and Ariel Feldstein, chief scientific officer for Internal Medicine at Pfizer. Their participation highlights a central question confronting the industry: how can pharmaceutical research become more productive while addressing biological processes that influence many diseases at once? Aging biology may offer a way to identify shared disease pathways, but it also raises difficult questions about clinical endpoints, patient selection, long-term safety and how regulators should evaluate therapies intended to preserve function across multiple organ systems.

Additional sessions will feature researchers and executives from Eli Lilly, Astellas, GSK, Daiichi Sankyo, Genentech, AstraZeneca, Novo Nordisk, Roche, Sanofi and Lundbeck, among other companies. Academic and medical scientists will be joined by editors and journalists associated with Nature Biotechnology, Nature Medicine, Nature Aging, TIME, the Financial Times, Forbes Health and Genetic Engineering & Biotechnology News. The presence of scientific media is particularly relevant as longevity research attracts extraordinary public attention, along with skepticism about exaggerated claims. Interventions that alter aging-related pathways must be distinguished from products marketed on the basis of weak evidence. Rigorous randomized clinical trials, validated biomarkers and transparent reporting will be essential if the field is to demonstrate that a treatment improves human health rather than merely changing a laboratory measurement.

Artificial intelligence will occupy a major part of the program. Computational systems are increasingly used to analyze biological datasets, identify disease-associated targets, predict molecular interactions and generate candidate compounds. In generative drug discovery, machine-learning models can search chemical space—the enormous universe of possible drug-like molecules—for structures predicted to bind a selected target or possess desirable pharmacological properties. Insilico Medicine has positioned AI-driven discovery at the center of its own development strategy, but the ARDD sessions will examine the technology in a broader context, including large-scale datasets for future AI systems, computational approaches to neurodegeneration, systems immunology and immune aging, and the potential use of AI in clinical trials. These applications could improve trial design by identifying patient subgroups, forecasting treatment response and monitoring biological changes over time, although algorithmic predictions still require experimental and clinical validation.

Dedicated forums will also examine Longevity Medicine, AI in Drug Discovery, Pet and Animal Longevity, and “Virtual Cell in Time: Virtual Aging Cell.” Virtual-cell research seeks to model how cells change across time and under different biological conditions, potentially allowing scientists to simulate disease processes or predict the effects of interventions before testing them in living systems. Animal longevity research may provide another route to discovery because companion animals experience naturally occurring diseases and aging processes in environments that can sometimes resemble human conditions more closely than laboratory models do. Yet translating results across species remains technically challenging. Differences in metabolism, immune function, lifespan and disease biology mean that an intervention that extends survival in an animal model may not produce the same benefit in people.

The investment and business-development program will bring together representatives of Deerfield, OrbiMed, Oaktree Capital Management, Qiming Venture Partners, UBS, Value Partners Group, Danaher Ventures, Morgan Stanley, LongeVC and other organizations. Their sessions will focus on capital formation, therapeutic partnering, licensing and the financial structures needed to support longevity drug development. Developing medicines that target aging-related biology can require long timelines because researchers may need to demonstrate effects on several diseases or functional outcomes rather than on one narrowly defined condition. Investors and companies must therefore assess not only scientific risk but also regulatory strategy, reimbursement, manufacturing feasibility and the commercial implications of therapies that could be prescribed across large aging populations.

Vadim Gladyshev, executive chair of ARDD and professor of medicine at Harvard Medical School, said the biology of aging has become one of biomedical science’s most promising frontiers, while emphasizing that the major challenge is translating fundamental discoveries into interventions that improve healthspan. Morten Scheibye-Knudsen, ARDD co-chair and professor at the University of Copenhagen, said the meeting’s relocation to Boston places it within one of the world’s strongest biomedical innovation ecosystems and reflects the field’s growing emphasis on medicines rather than theory alone. Their comments point to the defining issue for longevity biotechnology: scientific excitement must eventually be matched by measurable improvements in mobility, cognition, metabolic health, resilience and independence.

Insilico Medicine and Eli Lilly are serving as Tier 1 sponsors, with the McKinsey Health Institute as the sole knowledge partner. Additional support comes from AstraZeneca, AbbVie, Human Longevity, Nestlé, Dior, Maxwell Biosciences, BioAge Labs, Gordian Biotechnology, GlycanAge, LongeVC, AniVC, Tolerance Bio, Tally Health, the Institute for Healthier Living Abu Dhabi, Cambrian Bio, Biocytogen, TruDiagnostic and Cyclarity Therapeutics. Synaro Capital, The Cat Health Company and PranaGen Bioscience are Tier 4 sponsors, while Morgan Stanley, Estée Lauder Companies, the Intrinsic Capacity, Frailty & Sarcopenia Research Conference for Healthy Longevity, and quadraScope are listed as Tier 5 sponsors. Registration is open at www.agingpharma.org. Organizers describe ARDD as the world’s largest meeting dedicated to aging and longevity biotechnology, bringing together scientists, clinicians, companies, investors and policymakers to accelerate the conversion of discoveries in aging biology into practical therapeutic programs.

Subject of Research: Aging biology, longevity biotechnology, artificial intelligence in drug discovery, healthspan therapeutics, clinical development, regulatory strategy, investment and pharmaceutical research.

Article Title: ARDD 2026 to Bring Longevity Science, AI and Drug Development Leaders Together at Harvard

News Publication Date: August 20, 2026

Web References: www.agingpharma.org

References: Insilico Medicine announcement on the ARDD 2026 program; statements from Alex Zhavoronkov, Vadim Gladyshev and Morten Scheibye-Knudsen.

Image Credits: ARDD 2026 Program

Keywords: Aging research, longevity biotechnology, healthspan, artificial intelligence, drug discovery, generative AI, clinical trials, pharmaceutical research, aging biology, ARDD 2026, Harvard University, precision medicine, neurodegeneration, immune aging, longevity medicine.

Organized by Insilico Medicine, ARDD 2026 is being presented as a major meeting point for the longevity field at a moment when aging biology is moving beyond descriptive research and into therapeutic development. Researchers are investigating whether age-related decline can be slowed by targeting biological processes that influence multiple diseases at once, including chronic inflammation, cellular senescence, mitochondrial dysfunction, impaired protein maintenance, epigenetic change and the loss of regenerative capacity. The central premise is not simply that people should live longer, but that interventions aimed at the mechanisms of aging could delay or prevent several disorders simultaneously, potentially changing how medicine approaches cancer, cardiovascular disease, neurodegeneration, diabetes and frailty.

“The biology of aging has become one of the most promising frontiers in biomedical science,” said Vadim Gladyshev, executive chair of ARDD and professor of medicine at Harvard University. He described the field’s primary challenge as translating fundamental discoveries into interventions that improve healthspan, the period of life spent in good health. That translation requires more than identifying molecular pathways in laboratory organisms. It demands validated biomarkers, reproducible clinical endpoints, carefully designed trials and a clearer understanding of how biological age differs from chronological age. Conferences such as ARDD, Gladyshev said, can help connect researchers capable of asking fundamental questions with clinicians, companies and investors able to test and develop the resulting ideas.

Aging is not controlled by a single switch, and that complexity is one reason the field has attracted attention from multiple branches of science. Over time, cells accumulate DNA damage, lose epigenetic organization and become less efficient at repairing damaged proteins and organelles. Some cells enter a state known as senescence, in which they stop dividing but remain metabolically active and release inflammatory signals that can affect neighboring tissue. Mitochondria may produce energy less efficiently, while immune regulation becomes increasingly dysbalanced. These changes interact across organs, creating a biological network in which a modest disturbance in one system can amplify problems elsewhere. Drug developers are therefore exploring both targeted therapies and combinations designed to influence several aging-related mechanisms.

The scientific challenge is matched by a difficult regulatory and clinical question: aging itself is not generally treated as a single disease indication. Instead, prospective therapies may initially be tested against specific conditions or functional outcomes associated with aging. Scientists are developing measurements that could reveal whether a treatment changes the pace of biological decline, including molecular clocks based on DNA methylation, proteomic signatures, inflammatory markers, imaging measurements and assessments of physical resilience. These tools remain under active evaluation, but their progress could help determine whether a candidate drug is affecting the underlying biology of aging or merely treating one symptom after it appears. The success of the field may depend on establishing which biomarkers reliably predict meaningful improvements in everyday health.

ARDD 2026 will bring together representatives from ten of the world’s leading pharmaceutical companies, along with academic institutions, biotechnology companies, entrepreneurs and institutional investors. The meeting’s organizers describe this cross-sector structure as essential because longevity research sits at the intersection of basic biology, drug discovery, clinical medicine and health economics. Discoveries made in cell cultures or animal models must pass through increasingly demanding stages of optimization, toxicology testing and human trials. At the same time, companies must determine whether a proposed target can be modulated safely for years, whether the treatment can be manufactured at scale and whether patients and health systems will recognize a measurable benefit.

“ARDD has always been about bringing together the world’s leading minds in aging research to accelerate the development of interventions that extend healthy lifespan,” said Morten Scheibye-Knudsen, co-chair of ARDD and associate professor at the University of Copenhagen. He said the decision to move the conference to Boston represents a new phase for the event by placing it within one of the world’s strongest biomedical innovation ecosystems. Boston and Cambridge host major universities, hospitals, biotechnology companies, venture funds and pharmaceutical research centers, creating an unusually dense environment for collaboration between researchers who discover potential mechanisms and teams that develop them into medicines. Scheibye-Knudsen emphasized that the 2026 program will focus strongly on translating scientific discoveries into therapeutic programs.

The meeting’s sponsorship structure reflects the growing commercial interest in longevity biotechnology. Insilico Medicine and Eli Lilly are identified as Tier 1 sponsors, while the McKinsey Health Institute will serve as the sole knowledge partner. Tier 3 sponsors include AbbVie, AniVC, AstraZeneca, BioAge Labs, Biocytogen, Cambrian Bio, Cyclarity Therapeutics, Dior, GlycanAge, Gordian Biotechnology, Human Longevity, the Institute for Healthier Living Abu Dhabi, LongeVC, Maxwell Biosciences, Nestlé, Tally Health and TruDiagnostic. Synaro Capital, The Cat Health Company and PranaGen Bioscience are listed as Tier 4 sponsors. Estée Lauder, Morgan Stanley, the Intrinsic Capacity Frailty & Sarcopenia Research Conference for Healthy Longevity and QuadraScope are supporting the event as Tier 5 sponsors.

The breadth of organizations involved illustrates how aging research is expanding beyond conventional pharmaceutical development. Some companies are pursuing small-molecule drugs that alter signaling pathways or remove dysfunctional cells; others are developing biological therapies, computational platforms, diagnostics, nutritional interventions and systems for measuring biological age. Artificial intelligence is also becoming part of the discovery process, with researchers using machine-learning models to analyze large collections of molecular, clinical and imaging data, identify patterns linked to disease risk and propose drug candidates. Such tools can accelerate hypothesis generation, but they do not remove the need for experimental validation. A predicted target must still demonstrate biological relevance, therapeutic selectivity and safety in rigorous studies.

Alex Zhavoronkov, Ph.D., co-chair of ARDD and chief executive officer of Insilico Medicine, said the conference has served for more than a decade as a global platform for dialogue among academia, pharmaceutical companies, startups and investors. He characterized the current momentum as evidence that longevity biotechnology has become a significant component of modern drug discovery and health economics. The claim reflects a broader change in how aging is viewed: rather than treating age as an unavoidable background risk factor, researchers are increasingly examining it as a modifiable biological state that influences the probability of many diseases. Whether that approach will produce broadly effective therapies remains uncertain, but the number of companies, clinical programs and research collaborations entering the field has made the question impossible for mainstream medicine to ignore.

Now in its 13th year, the Aging Research & Drug Discovery Meeting is described by its organizers as the world’s largest meeting dedicated to aging and longevity biotechnology. The 2026 gathering at Harvard’s David Rubenstein Treehouse will focus on the scientific and practical steps required to move discoveries from laboratories into real-world research and therapeutic programs. The Nordic Aging Society, a nonprofit scientific organization dedicated to research on the biology of aging and collaboration across the Nordic region and beyond, is supporting the meeting. As the field gathers in Boston, the most important test for longevity science will not be the scale of its financial backing or the number of ambitious predictions, but whether carefully designed studies can show that targeting aging biology produces durable improvements in human health, function and independence.

Subject of Research: Aging biology, longevity biotechnology, and the translation of aging research into therapeutic drug-development programs.

Article Title: Former Takeda CEO Christophe Weber to Speak at ARDD 2026 as Longevity Science Accelerates Toward Therapeutic Development

News Publication Date: August 7, 2026

Web References: https://agingpharma.org

Image Credits: ARDD 2026

Keywords: aging research, longevity biotechnology, drug discovery, healthspan, biological aging, ARDD 2026, Christophe Weber, Insilico Medicine, pharmaceutical research, senescence, biomarkers, precision medicine